Security
Intellia Therapeutics, Inc. Common Stock · NTLA
NTLANASDAQCommon stockCurrentCIK 1652130Updated Nov 3, 2026
NTLA price & chart
Loading TradingView…
NASDAQ:NTLA on TradingView ↗About the company
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.
In the news
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ↗
The Credibility Filter Wall Street Uses to Sort Biotech Winners ↗
Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation News provided by Shareholders Foundation, Inc. Apr 23, 2025, 09:50 ET Share this article Share to X Share this article Share to X SAN DIEGO , April 23, 2025 /PRNewswire/ -- Sharehol ↗
Recent filings
144 filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Regulation FD Disclosure
Items 1.01, 2.03, 7.01, 9.01
4 filing
144 filing
Show 5 more recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
4 filing
144 filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 925,275,000Source | 1,173,351,000Source | 857,164,000Source | 898,894,000Source | 1,191,536,000Source | 758,779,000Source | 986,163,000Source | 1,259,589,000Source | 842,127,000Source | 1,191,015,000Source | 1,300,977,000Source | 1,520,114,000Source |
| Property, Plant and Equipment, NetUSD | 20,421,000Source | 28,763,000Source | 15,058,000Source | 22,806,000Source | 30,273,000Source | 15,516,000Source | 25,123,000Source | 32,075,000Source | 17,671,000Source | 27,381,000Source | 32,760,000Source | 27,921,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 193,389,000Source | 120,495,000Source | 106,128,000Source | 156,172,000Source | 130,849,000Source | 134,697,000Source | 126,880,000Source | 171,979,000Source | 155,464,000Source | 189,182,000Source | 226,748,000Source | 523,506,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 11,050,000Source | 8,854,000Source | 7,321,000Source | 11,353,000Source | 12,329,000Source | 9,131,000Source | 10,504,000Source | 36,427,000Source | 9,468,000Source | 8,517,000Source | 36,456,000Source | 3,768,000Source |
| Assets, CurrentUSD | 581,941,000Source | 710,902,000Source | 527,832,000Source | 495,945,000Source | 757,211,000Source | 466,449,000Source | 551,392,000Source | 884,043,000Source | 527,711,000Source | 639,863,000Source | 998,330,000Source | 1,216,797,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 59,847,000Source | 43,934,000Source | 82,752,000Source | 24,941,000Source | 53,814,000Source | 81,332,000Source | 37,141,000Source | 56,322,000Source | 68,359,000Source | 29,831,000Source | 49,651,000Source | 20,407,000Source |
| Operating Lease, Right-of-Use AssetUSD | 117,883,000Source | 100,331,000Source | 85,954,000Source | 129,045,000Source | 105,412,000Source | 97,543,000Source | 137,979,000Source | 110,424,000Source | 105,955,000Source | 219,292,000Source | 115,375,000Source | 133,076,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 176,853,000Source | 210,736,000Source | 129,458,000Source | 183,639,000Source | 220,474,000Source | 137,840,000Source | 206,244,000Source | 223,452,000Source | 170,733,000Source | 319,059,000Source | 250,808,000Source | — |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 12,000Source | 10,000Source | 14,000Source | 10,000Source | 10,000Source | 12,000Source | 10,000Source | 10,000Source | 12,000Source | 10,000Source | 9,000Source | 9,000Source |
| Retained Earnings (Accumulated Deficit)USD | -2,494,308,000Source | -2,048,502,000Source | -2,792,959,000Source | -2,392,984,000Source | -1,912,790,000Source | -2,686,325,000Source | -2,291,729,000Source | -1,765,815,000Source | -2,590,094,000Source | -2,177,400,000Source | -1,658,379,000Source | -1,177,187,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 990,000Source | 3,297,000Source | -1,030,000Source | 653,000Source | -1,155,000Source | -240,000Source | 1,057,000Source | -947,000Source | 1,032,000Source | 605,000Source | -2,258,000Source | -7,461,000Source |
| Stockholders' Equity Attributable to ParentUSD | 748,422,000Source | 962,615,000Source | 727,706,000Source | -715,255,000Source | 971,062,000Source | 620,939,000Source | 779,919,000Source | 1,036,137,000Source | 671,394,000Source | 871,956,000Source | 1,050,169,000Source | 1,235,584,000Source |
| Additional Paid in Capital, Common StockUSD | 3,241,728,000Source | 3,007,810,000Source | 3,521,681,000Source | 3,107,576,000Source | 2,884,997,000Source | 3,307,492,000Source | 3,070,581,000Source | 2,802,889,000Source | 3,260,444,000Source | 3,048,741,000Source | 2,710,797,000Source | 2,420,223,000Source |
| Liabilities and EquityUSD | 925,275,000Source | 1,173,351,000Source | 857,164,000Source | 898,894,000Source | 1,191,536,000Source | 758,779,000Source | 986,163,000Source | 1,259,589,000Source | 842,127,000Source | 1,191,015,000Source | 1,300,977,000Source | 1,520,114,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 93,726,000Source | 105,683,000Source | 79,392,000Source | 95,499,000Source | 105,090,000Source | 76,445,000Source | 112,593,000Source | 97,912,000Source | 103,884,000Source | 110,851,000Source | 115,208,000Source | 126,554,000Source |
| Operating Lease, Liability, CurrentUSD | 27,378,000Source | 19,177,000Source | 23,344,000Source | 26,990,000Source | 18,963,000Source | 19,095,000Source | 38,763,000Source | 18,763,000Source | 26,480,000Source | 20,246,000Source | 18,599,000Source | 16,685,000Source |
| Accounts Payable, CurrentUSD | 13,260,000Source | 13,145,000Source | 11,714,000Source | 9,802,000Source | 18,816,000Source | 18,800,000Source | 12,364,000Source | 13,689,000Source | 20,252,000Source | 14,589,000Source | 7,452,000Source | 5,154,000Source |
| Operating Lease, Liability, NoncurrentUSD | 70,588,000Source | 82,446,000Source | 50,066,000Source | 75,601,000Source | 87,332,000Source | 61,395,000Source | 80,490,000Source | 92,100,000Source | 66,849,000Source | 189,952,000Source | 96,747,000Source | 114,018,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 40,841,000Source | 51,206,000Source | 44,334,000Source | 41,553,000Source | 45,127,000Source | 37,920,000Source | 40,805,000Source | 43,276,000Source | 49,862,000Source | 55,355,000Source | 67,017,000Source | 60,876,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -96,231,000Source | -114,329,000Source | -412,694,000Source | -519,021,000Source | -481,192,000Source | -474,186,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | 2,400,000Source | 2,600,000Source | 2,100,000Source | 2,500,000Source | 2,202,000Source | 2,498,000Source | 9,767,000Source | 10,285,000Source | 8,976,000Source | 7,572,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 13,479,000Source | 21,840,000Source | 80,219,000Source | 154,273,000Source | 134,050,000Source | 91,400,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -337,000Source | 1,987,000Source | 951,000Source | -27,939,000Source | 32,688,000Source | 1,737,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -1,420,000Source | -1,869,000Source | 5,987,000Source | 6,800,000Source | 2,522,000Source | -4,584,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -117,346,000Source | -148,930,000Source | -394,736,000Source | -348,880,000Source | -394,086,000Source | -333,287,000Source |
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | — | — | — | — | — | — | 287,000Source | 287,000Source | 287,000Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 66,310,000Source | 94,328,000Source | 228,031,000Source | 125,567,000Source | -31,347,000Source | 160,309,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 79,000Source | 735,000Source | 1,129,000Source | 5,778,000Source | 13,985,000Source | 13,558,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 33,569,000Source | 0Source | 131,486,000Source | 185,747,000Source | 130,323,000Source | 582,955,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -17,467,000Source | -54,602,000Source | -35,219,000Source | -37,566,000Source | -295,110,000Source | 409,977,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 19,604,000Source | 39,619,000Source | 18,075,000Source | 22,036,000Source | 13,479,000Source | 21,840,000Source | 80,219,000Source | 154,273,000Source | 134,050,000Source | 91,400,000Source |
| AssetAcquisitionContingentConsiderationLiabilityUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 10,541,000Source |
| Gain (Loss) on InvestmentsUSD | — | — | 3,439,000Source | -3,064,000Source | 329,000Source | 1,339,000Source | -904,000Source | -2,125,000Source | -899,000Source | -32,565,000Source | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | -527,000Source | 76,000Source | -72,000Source | 162,000Source |
| General and Administrative ExpenseUSD | — | — | 30,512,000Source | 30,501,000Source | 37,824,000Source | 27,206,000Source | 34,843,000Source | 29,007,000Source | 119,800,000Source | 125,829,000Source | 116,497,000Source | 90,306,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | 0Source | — | — | — | — | 0Source | 0Source | -15,633,000Source | -11,079,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Investment Income, InterestUSD | — | — | 6,714,000Source | 12,122,000Source | 5,797,000Source | 7,402,000Source | 5,205,000Source | 8,603,000Source | 29,195,000Source | 47,807,000Source | 49,832,000Source | 8,542,000Source |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | 337,000Source | 4,452,000Source | -790,000Source | -404,000Source | -1,272,000Source | 452,000Source | 427,000Source | 731,000Source | 3,635,000Source | -1,637,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -101,324,000Source | -135,712,000Source | -106,634,000Source | -101,255,000Source | -96,231,000Source | -114,329,000Source | -412,694,000Source | -519,021,000Source | -481,192,000Source | -474,186,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 10,153,000Source | 9,058,000Source | 6,126,000Source | 8,741,000Source | 4,301,000Source | 6,478,000Source | 28,296,000Source | 15,242,000Source | 34,099,000Source | -16,022,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 194,600,000Source | — | 128,175,000Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | 0Source | 722,000Source | 5,862,000Source | 6,599,000Source | 14,517,000Source |
| Realized Investment Gains (Losses)USD | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | — | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | — | — | — | — | — | 6,600,000Source | 11,400,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 13,782,000Source | 9,111,000Source | 7,659,000Source | 14,245,000Source | 15,048,000Source | 16,627,000Source | 67,671,000Source | 57,877,000Source | 36,275,000Source | 52,121,000Source |
| Operating Income (Loss)USD | — | — | -111,477,000Source | -144,770,000Source | -112,760,000Source | -109,996,000Source | -100,532,000Source | -120,807,000Source | -440,990,000Source | -534,263,000Source | -515,291,000Source | -458,164,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 10,153,000Source | 9,058,000Source | 6,126,000Source | 8,741,000Source | 4,301,000Source | 6,478,000Source | 28,296,000Source | 15,242,000Source | 34,099,000Source | -16,022,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -101,324,000Source | -135,712,000Source | -106,634,000Source | -101,255,000Source | -96,231,000Source | -114,329,000Source | -412,694,000Source | -519,021,000Source | -481,192,000Source | -474,186,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.92Source | -1.34Source | -0.8Source | -0.98Source | -0.81Source | -1.1Source | -3.81Source | -5.25Source | -5.42Source | -6.16Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.92Source | -1.34Source | -0.8Source | -0.98Source | -0.81Source | -1.1Source | -3.81Source | -5.25Source | -5.42Source | -6.16Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 110,188,000Source | 101,002,000Source | 133,480,000Source | 103,732,000Source | 118,490,000Source | 103,500,000Source | 108,376,000Source | 98,849,000Source | 88,770,000Source | 76,972,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 110,188,000Source | 101,002,000Source | 133,480,000Source | 103,732,000Source | 118,490,000Source | 103,500,000Source | 108,376,000Source | 98,849,000Source | 88,770,000Source | 76,972,000Source |
| Additional Financial Items | ||||||||||||
| Costs and ExpensesUSD | — | — | 125,259,000Source | 153,881,000Source | 120,419,000Source | 124,241,000Source | 115,580,000Source | 137,434,000Source | 508,661,000Source | 592,140,000Source | 551,566,000Source | 510,285,000Source |
| Gain (Loss) on InvestmentsUSD | — | — | 3,439,000Source | -3,064,000Source | 329,000Source | 1,339,000Source | -904,000Source | -2,125,000Source | -899,000Source | -32,565,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 30,512,000Source | 30,501,000Source | 37,824,000Source | 27,206,000Source | 34,843,000Source | 29,007,000Source | 119,800,000Source | 125,829,000Source | 116,497,000Source | 90,306,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | 0Source | — | — | — | — | 0Source | 0Source | -15,633,000Source | -11,079,000Source |
| Investment Income, InterestUSD | — | — | 6,714,000Source | 12,122,000Source | 5,797,000Source | 7,402,000Source | 5,205,000Source | 8,603,000Source | 29,195,000Source | 47,807,000Source | 49,832,000Source | 8,542,000Source |
| Realized Investment Gains (Losses)USD | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | — | — |
| Research and Development ExpenseUSD | — | — | 94,747,000Source | 123,380,000Source | 82,595,000Source | 97,035,000Source | 80,737,000Source | 108,427,000Source | 388,861,000Source | 466,311,000Source | 435,069,000Source | 419,979,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | — | — | — | — | — | 6,600,000Source | 11,400,000Source |
Filing attachments
ntla-ex99_1.htm · 8-K · 2026-09-08
EX-99.1 2 ntla-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE) • FDA sets Prescription Drug User Fee Act (PDUFA) date of March 10, 2027 • Positions lonvo-z to be the world’s first in vivo CRISPR-based therapy and the only one-time HAE treatment, if approved CAMBRIDGE, Mass., September 8, 2026 -- Intellia Therapeutics, Inc. (Nasd…
Read attachment ↗d110798dex991.htm · 8-K · 2026-09-04
EX-99.1 2 d110798dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million $75 million funded upfront with an additional $325 million tied to milestones, providing strategic flexibility through anticipated value inflection points CAMBRIDGE, Mass., September 4, 2026 - Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing …
Read attachment ↗ntla-ex99_1.htm · 8-K · 2026-08-06
EX-99.1 2 ntla-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates - Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of Medicine - Anticipate FDA acceptance of BLA for lonvo-z in second half of 2026 and U.S. launch in first half of 2027 - Enrollment successfully reinitiated in nex-z Phase 3 clinical trials; MAGNITUDE-2 enrollment in ATTRv-PN expe…
Read attachment ↗ntla-ex99_1.htm · 8-K · 2026-06-15
EX-99.1 2 ntla-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema • Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026 • HAELO manuscript simultaneously published in the New England Journal of Medicine CAMBRIDGE, Mass., June 13, 2026 - Intellia Therap…
Read attachment ↗ntla-ex99_1.htm · 8-K · 2026-05-11
EX-99.1 2 ntla-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates - Presented positive Phase 3 HAELO topline clinical data for lonvo-z in HAE; initiated rolling BLA submission; anticipate U.S. launch in first half of 2027 - Recently resumed patient screening in MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nex-z in ATTR-CM and ATTRv-PN, respectively - Including proceeds from underwritten public offerin…
Read attachment ↗d138980dex991.htm · 8-K · 2026-04-27
EX-99.1 2 d138980dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 *** CONFIDENTIAL *** Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) met primary and all key secondary endpoints; favorable safety and tolerability data observed Single dose of lonvo-z freed most patients from both attacks and ongoing therapy for six-month efficacy evaluation period, demons…
Read attachment ↗